TriangleNCT02426125 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Randomization to Date of Death from Any Cause (Up to 31.1 Months)
What was measured
OS is the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date prior to the data inclusion cutoff date.
Analysis population: All randomized participants. Censored participants: Ramucirumab + Docetaxel = 78, Placebo + Docetaxel = 67.
Groups in this outcome
Ramucirumab + Docetaxel
Ramucirumab (10 mg/kg) IV plus docetaxel IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Placebo + Docetaxel
Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
| Group | Source count |
|---|---|
| Ramucirumab + Docetaxel | 263 |
| Placebo + Docetaxel | 267 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ramucirumab + Docetaxel | 9.40 | Not reported | 7.89 | 11.43 | Not reported |
| Placebo + Docetaxel | 7.85 | Not reported | 7.00 | 9.30 | Not reported |
Source statistical analyses
- ci Lower Limit
- 0.724
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.086
- estimate Comment
- Stratified
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.2461
- p Value Comment
- Stratified
- param Type
- Hazard Ratio (HR)
- param Value
- 0.887
- statistical Method
- Log Rank
Complete source fields
- analyses
- ci Lower Limit
- 0.724
- ci Num Sides
- TWO_SIDED
- ci Pct Value
- 95
- ci Upper Limit
- 1.086
- estimate Comment
- Stratified
- group Ids
- OG000
- OG001
- non Inferiority Type
- SUPERIORITY
- p Value
- 0.2461
- p Value Comment
- Stratified
- param Type
- Hazard Ratio (HR)
- param Value
- 0.887
- statistical Method
- Log Rank
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 7.89
- upper Limit
- 11.43
- value
- 9.40
- group Id
- OG001
- lower Limit
- 7.00
- upper Limit
- 9.30
- value
- 7.85
- denoms
- counts
- group Id
- OG000
- value
- 263
- group Id
- OG001
- value
- 267
- units
- Participants
- description
- OS is the time from the date of randomization to the date of death from any cause. For each participant who is not known to have died as of the data inclusion cutoff date for a particular analysis, OS was censored for that analysis at the last known alive date prior to the data inclusion cutoff date.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Ramucirumab (10 mg/kg) IV plus docetaxel IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
- id
- OG000
- title
- Ramucirumab + Docetaxel
- description
- Placebo IV plus docetaxel (75 mg/m²) IV on day 1 of each 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
- id
- OG001
- title
- Placebo + Docetaxel
- param Type
- MEDIAN
- population Description
- All randomized participants. Censored participants: Ramucirumab + Docetaxel = 78, Placebo + Docetaxel = 67.
- reporting Status
- POSTED
- time Frame
- Randomization to Date of Death from Any Cause (Up to 31.1 Months)
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice